EEG correlates of acute and chronic paroxetine treatment in depression

Journal of Affective Disorders

Volumn 69, Issue 1-3, 2002, Pages 241-249

  Knott, Verner ^a   Mahoney, Colleen ^a   Kennedy, Sidney ^b   Evans, Kenneth ^c  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Depression; Electroencephalography; Paroxetine; Serotonin; Treatment outcome

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; ELECTROENCEPHALOGRAM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RATING SCALE; SEDATION; ELECTROENCEPHALOGRAPHY; MAJOR DEPRESSION; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION, INVOLUTIONAL; ELECTROENCEPHALOGRAPHY; HUMAN; MALE; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SUPPORT, NON-U.S. GOV'T; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 0036018513     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(01)00308-1     Document Type: Article

References (30)

1. Brain metabolic changes in major depressive disorder from pre-to post-treatment with paroxetine
2. Paroxetine: A selective serotonin reuptake inhibiting antidepressant
3. Confirmatory and exploratory analysis applied to pharmaco-EEG and related study data: Contradiction or useful enhancement
4. EEG and psychopharmacology
5. A rating scale for depression
6. The EEG in psychiatry, an outline with summarized points and references
7. Quantitative EEG brain mapping in psychotropic drug development, drug treatment selection, and monitoring
8. The E-adjustment procedure for repeated measures analyses of variance
9. Normative data banks and neurometrics: Basic concepts, methods and results of norm constructions
10. Effects of the selective 5-hydroxytryptamine uptake inhibitors paroxetine and zimeldine on EEG sleep and waking stages
11. Computerized EEG correlates of depression and antidepressant treatment
12. Quantitative EEG methods 2nd measures in human psychopharmacological research
13. Right hemisphere abnormalities in major depression: Quantitative electroencephalographic findings before and after treatment
14. Paroxetine: Pharmacokinetics tolerance and depletion of blood 5-HT in man
15. EEG assessment of the sedative and excitatory properties of CNS-active compounds in the patients with depression
16. EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers
17. The effect of paroxetine on the quantitative EEG
18. Treatment-resistant depression in the age of serotonin
19. Quantitative, waking EEG research on depression
20. Neurochemical alterations of serotonergic neuronal systems in depression
21. Pharmaco-EEG profiles of typical and atypical antidepressants
22. The use of pharmaco-EEG in drug profiling
23. EEG imaging of brain activity in clinical pharmacopsychiatry
24. Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses
25. On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine
26. Clovoxamine and Fluvoxamine-2 biogenicamine re-uptake inhibiting antidepressants: Quantitative EEG, psychometric and pharmacokinetic studies in man
27. Fluoxetine, amitriptyline and the electroencephalogram